AstraZeneca PLC (AZN)
NYSE: AZNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
AZN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $248.33B
- P/E (TTM)
- 23.93
- Forward P/E
- 13.85
- EPS (TTM)
- $6.69
- Dividend yield
- 2.02% ($3.23)
- Ex-dividend date
- Feb 19, 2026
- 52-week range
- 153.41 – 212.71
- Day range
- 158.53 – 161.29
- Volume / Avg
- 2.36M / 3.41M
- Beta
- —
- Shares outstanding
- 1.55B
- Next earnings
- Oct 30, 2026
52-week range
AZN stock today
Shares of AstraZeneca (AZN) finished higher on Oct 7 at $160.12, a gain of 0.95% or $1.51 per share, versus the S&P 500's 0.22% decline. Shares are 24.7% below their 52-week high of $212.71, set on Feb 18, 2026 and 4.4% above the 52-week low of $153.41, near the bottom of the past year's range. AZN is down 12.9% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 6.8%.
At 23.9x trailing earnings, AstraZeneca trades above the peer-group median of 21.0x. Its forward P/E of 13.8x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. AstraZeneca's next earnings report is expected on Oct 30, 2026. AstraZeneca pays an annual dividend of $3.23 per share, a 2.02% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About AstraZeneca
Company profileAstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.
- Headquarters
- Cambridge
- Employees
- 96,100
- IPO year
- 2026
- Website
- astrazeneca.com
Financial highlights
Full financialsIn fiscal 2025, AstraZeneca generated $58.74 billion in revenue, up 8.6% from fiscal 2024, its 7th consecutive year of revenue growth. Net income was $10.22 billion (+45.3% year over year), for a net margin of 17.4% versus a median of 12.0% in the prior 5 years. Gross margin was 81.9% (up from 81.1%) and operating margin 23.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $58.74B | $54.07B | $45.81B | $44.35B | $37.42B |
| Growth | +8.63% | +18.03% | +3.29% | +18.53% | +40.58% |
| Net income | $10.22B | $7.04B | $5.96B | $3.29B | $112.00M |
| EPS (diluted) | $6.54 | $4.50 | $3.81 | $2.11 | $0.08 |
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$211.35+31.99%
- Strong buy 3
- Buy 7
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 30, 2026
- EPS estimate
- $2.16
Dividends
Dividend history- Annual dividend
- $3.23
- Dividend yield
- 2.02%
- Last payment
- $2.15
- Ex-dividend date
- Feb 19, 2026
AZN news
All AZN news- Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?NasdaqIRWD, AZN, ABBV
- Astrazeneca (AZN) Exceeds Market Returns: Some Facts to ConsiderNasdaq
- Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity?NasdaqMRK, AZN, MRNA
- AstraZeneca Opens New $1 Bln R&D Hub To Strengthen Global Drug ResearchNasdaq
- AstraZeneca CEO Soriot says drugmaker can grow without big acquisitionSeeking Alpha
- SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway CombosNasdaqSMMT, AZN, PFE
- FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line SettingNasdaqLLY, AZN, JNJ, ABBV
- Summit Therapeutics Secures $2B Strategic Investment From AstraZenecaNasdaqAZN, SMMT
AstraZeneca peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NVSNovartis AG | 143.28 | +1.77% | $272.33B | vs AZN |
| ABTAbbott Laboratories | 98.73 | +0.58% | $170.84B | vs AZN |
| NVONovo Nordisk A/S | 38.26 | +1.95% | $168.89B | vs AZN |
| MRKMerck & Company Inc. | 142.79 | +0.60% | $352.29B | vs AZN |
| VRTXVertex Pharmaceuticals Incorporated | 505.64 | +0.66% | $128.16B | vs AZN |
| BMYBristol-Myers Squibb Company | 59.70 | +0.18% | $121.95B | vs AZN |
| SNYSanofi ADS | 40.20 | +1.62% | $96.32B | vs AZN |
| REGNRegeneron Pharmaceuticals Inc. | 742.12 | +0.46% | $76.40B | vs AZN |
Indexes, lists and sector
AstraZeneca stock FAQ
What is AstraZeneca's stock price today?
AZN last traded at $160.12 as of Oct 7, 4:00 PM EDT, up 0.95% on the day. Prices are delayed at least 15 minutes.
Does AstraZeneca pay a dividend?
Yes. AstraZeneca pays $3.23 per share annually, a 2.02% yield. The most recent dividend of $2.15 had an ex-dividend date of Feb 19, 2026.
When is AstraZeneca's next earnings date?
AstraZeneca is expected to report earnings on Friday, October 30, 2026. Analysts expect EPS of $2.16.
What is AZN's P/E ratio?
AZN trades at a trailing P/E ratio of 23.93 and a forward P/E of 13.85, compared with a median of 21.0 for its closest peers.
Who is AstraZeneca's CEO?
Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. is the chief executive officer of AstraZeneca PLC, which has about 96,100 employees.
Has AZN ever split its stock?
Yes. The most recent AZN stock split was a 1-for-2 split on Feb 2, 2026, one of 3 splits on record.
What is the AZN 52-week high?
The 52-week high for AZN is $212.71 and the 52-week low is $153.41. The stock is currently 24.7% below its high.